Ionis Pharmaceuticals, Inc. (IONS)

NASDAQ: IONS · IEX Real-Time Price · USD
44.72
+0.31 (0.70%)
Aug 16, 2022 11:42 AM EDT - Market open
0.70%
Market Cap 6.35B
Revenue (ttm) 848.81M
Net Income (ttm) -28.15M
Shares Out 141.94M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE 90.91
Dividend n/a
Ex-Dividend Date n/a
Volume 159,915
Open 44.36
Previous Close 44.41
Day's Range 43.76 - 44.78
52-Week Range 25.04 - 46.15
Beta 0.70
Analysts Buy
Price Target 48.39 (+8.2%)
Earnings Date Aug 9, 2022

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcuta... [Read more...]

Industry Biotechnology
IPO Date May 17, 1991
CEO Brett Monia
Employees 660
Stock Exchange NASDAQ
Ticker Symbol IONS
Full Company Profile

Financial Performance

In 2021, IONS's revenue was $810.46 million, an increase of 11.13% compared to the previous year's $729.26 million. Losses were -$28.60 million, -93.56% less than in 2020.

Financial Statements

Analyst Forecast

According to 28 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is 48.39, which is an increase of 8.21% from the latest price.

Price Target
$48.39
(8.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down

Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates.

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss

Ionis Pharmaceuticals broadly missed second-quarter expectations Tuesday but reiterated its 2022 outlook and IONS stock inched up. The post Ionis Pharma Extends Breakout; Biotech Restates Guide Despite ...

Ionis reports second quarter financial results and recent business achievements

Reported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22 Tofersen NDA under priority review, PDUFA January 25, 2023 Completed enrollment in pelacarsen Lp(a) HORIZON and olezarsen BALAN...

Why Ionis Pharmaceuticals (IONS) Might Surprise This Earnings Season

Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 Stocks to Buy Ahead of Earnings Results Next Week

Five companies are slated to beat earnings estimates next week. These are: TTWO, IONS, CELH, LMND and GO.

Other symbols: CELHGOLMNDTTWO

2 Growth Stocks That Are Unapologetically Crushing the Bear Market

There's more than one factor driving recent outperformance of these shares.

Other symbols: JAZZ

Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thromboti...

Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis Fesomersen demonstrated substantial and statistically significant reductions ...

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis to hold second quarter 2022 financial results webcast

Webcast scheduled for Tuesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form...

SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S., it is progressive, leads to the loss of everyday functions and is uniformly fatal If approved, tofersen would be...

7 Undervalued Biotech Stocks to Buy Before They Boom

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. The post 7 Undervalued Biotech Stocks to Buy Before They Boom appeared ...

Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment

Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.

Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen

Pelacarsen is a potentially first-in-class treatment specifically targeting elevated lipoprotein(a) (Lp(a)), an independent, inherited and causal risk factor for cardiovascular disease There are current...

Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference

CARLSBAD, Calif., July 13, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a virtual fireside chat at the H.C.

Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug

Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.

Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study

- Positive data from a Phase 2 study of IONIS-FB-LRx support further development for treatment of patients with IgA nephropathy CARLSBAD, Calif. , July 11, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, In...

7 Best Biotech Stocks to Buy in July 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared f...

Other symbols: AMGNCRSPEXELIBBMRKTWST

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Li...

-       Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B -       Phase 3 clinical study evaluating b ...

Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year

U.S.-listed shares of AstraZeneca AZN, +2.98% were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its prima...

Other symbols: AZN

Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansfor...

-  Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN -  Eplontersen demonstrated a favorable safety profile -  Ionis and AstraZeneca expect...

Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag

The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.

Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA

CARLSBAD, Calif. , June 13, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has...

5 Cathie Wood Stocks to Buy in June

Despite the recent selloff, these five Cathie Wood stocks are likely to bounce back thanks to their focus on impressive innovation. The post 5 Cathie Wood Stocks to Buy in June appeared first on Investo...

Other symbols: EXASKTOSPATHTRMB